Ovid Therapeutics (OVID) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript [Seeking Alpha]
Ovid Therapeutics (OVID) had its price target raised by HC Wainwright from $2.00 to $4.00. They now have a "buy" rating on the stock.
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Ovid Therapeutics (OVID) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.